The Early- and Intermediate-Term Toxicity to Primitive Hematopoietic Progenitor Cells of Three Chemotherapy Regimens for Advanced Hodgkin Lymphoma
The early stem cell reservoir can be impaired by a few cycles of chemotherapy, and this impairment might persist after normalization of peripheral cytopenias. We directly evaluated the damage caused to marrow progenitor cells by 3 currently used chemotherapy regimens for advanced Hodgkin lymphoma. B...
Gespeichert in:
| Veröffentlicht in: | Clinical lymphoma & myeloma 2009-12, Vol.9 (6), p.425-429 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 429 |
|---|---|
| container_issue | 6 |
| container_start_page | 425 |
| container_title | Clinical lymphoma & myeloma |
| container_volume | 9 |
| creator | Gobbi, Paolo G. Rosti, Vittorio Valentino, Francesco Bonetti, Elisa Merli, Francesco Stelitano, Caterina Dondi, Alessandra Quarta, Giovanni Falorio, Simona Federico, Massimo |
| description | The early stem cell reservoir can be impaired by a few cycles of chemotherapy, and this impairment might persist after normalization of peripheral cytopenias. We directly evaluated the damage caused to marrow progenitor cells by 3 currently used chemotherapy regimens for advanced Hodgkin lymphoma.
Bone marrow samples from 37 patients randomly treated according to either the ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine), COPPEBVCAD (cyclophosphamide/vincristine/procarbazine/prednisone/epirubicin/bleomycin/vinblastine/lomustine/melphalan/vindesine), or BEACOPP (bleomycin/etoposide/doxorubicin/cyclophosphamide/vincristine/procarbazine/prednisone)schedule were taken a few days before the start of chemotherapy and 30 days and 6 months after its completion. Samples were cryopreserved, thawed in a single session, and cultured for 5 weeks to detect long-term culture-initiating cells (LTC-IC).
On the basis of the numbers of LTC-IC detected and of their relative variations, the ABVD regimen was associated with the least early reduction and the best late recovery of LTC-IC. COPPEBVCAD produced the greatest early damage, but recovery was nearly complete by 6 months. BEACOPP caused intermediate early toxicity that persisted at 6 months.
The different late toxicity exerted on marrow progenitors by these chemotherapy regimens should be carefully weighed in relation to both the expected early response rate and subsequent possibility of rescue in the case of first treatment failure. |
| doi_str_mv | 10.3816/CLM.2009.n.084 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_21340736</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1557919011700336</els_id><sourcerecordid>21340736</sourcerecordid><originalsourceid>FETCH-LOGICAL-c374t-9f36f0e7db94e3b271d47ed7bcb69776abe3384ea697161c8e6eaacc7b03ff83</originalsourceid><addsrcrecordid>eNp1kcFv2yAYxa1p09q1ve44cdrNHgTHwLGy2qVSplaT7wjD55gtBg9IVP8b-4tHlEg97fS9D_14gveK4jPBFeWk-dZuf1QrjEXlKszrd8U1EZSXmJHV-6zXa1YKIvBV8SnGXxjXa8LIx-KKCLEmnJPr4m83AnpQYb-USDmDnlyCMIGxKkHZZYk6_2q1TQtKHr0EO9lkj4A2MKnkZ28hWZ3P_Q6cTT6gFvb7iPyAujEAoHaEyacRgpoX9BN2dgIX0ZDBe3NUToNBG292v61D22WaRz-p2-LDoPYR7i7zpugeH7p2U26fvz-199tSU1anUgy0GTAw04saaL9ixNQMDOt13wjGGtUDpbwGlTfSEM2hAaW0Zj2mw8DpTfH1bDsH_-cAMcnJRp1frxz4Q5QrQmvMaJPB6gzq4GMMMMg5x6DCIgmWpxJkLkGeSpBO5hLyhS8X50Ofo3zDL6lngJ8ByN87WggyagunMGwAnaTx9n_e_wCxVJjn</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>21340736</pqid></control><display><type>article</type><title>The Early- and Intermediate-Term Toxicity to Primitive Hematopoietic Progenitor Cells of Three Chemotherapy Regimens for Advanced Hodgkin Lymphoma</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Gobbi, Paolo G. ; Rosti, Vittorio ; Valentino, Francesco ; Bonetti, Elisa ; Merli, Francesco ; Stelitano, Caterina ; Dondi, Alessandra ; Quarta, Giovanni ; Falorio, Simona ; Federico, Massimo</creator><creatorcontrib>Gobbi, Paolo G. ; Rosti, Vittorio ; Valentino, Francesco ; Bonetti, Elisa ; Merli, Francesco ; Stelitano, Caterina ; Dondi, Alessandra ; Quarta, Giovanni ; Falorio, Simona ; Federico, Massimo</creatorcontrib><description>The early stem cell reservoir can be impaired by a few cycles of chemotherapy, and this impairment might persist after normalization of peripheral cytopenias. We directly evaluated the damage caused to marrow progenitor cells by 3 currently used chemotherapy regimens for advanced Hodgkin lymphoma.
Bone marrow samples from 37 patients randomly treated according to either the ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine), COPPEBVCAD (cyclophosphamide/vincristine/procarbazine/prednisone/epirubicin/bleomycin/vinblastine/lomustine/melphalan/vindesine), or BEACOPP (bleomycin/etoposide/doxorubicin/cyclophosphamide/vincristine/procarbazine/prednisone)schedule were taken a few days before the start of chemotherapy and 30 days and 6 months after its completion. Samples were cryopreserved, thawed in a single session, and cultured for 5 weeks to detect long-term culture-initiating cells (LTC-IC).
On the basis of the numbers of LTC-IC detected and of their relative variations, the ABVD regimen was associated with the least early reduction and the best late recovery of LTC-IC. COPPEBVCAD produced the greatest early damage, but recovery was nearly complete by 6 months. BEACOPP caused intermediate early toxicity that persisted at 6 months.
The different late toxicity exerted on marrow progenitors by these chemotherapy regimens should be carefully weighed in relation to both the expected early response rate and subsequent possibility of rescue in the case of first treatment failure.</description><identifier>ISSN: 1557-9190</identifier><identifier>EISSN: 1938-0712</identifier><identifier>DOI: 10.3816/CLM.2009.n.084</identifier><identifier>PMID: 19951881</identifier><language>eng</language><publisher>United States</publisher><subject>ABVD ; Adolescent ; Adult ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; BEACOPP ; Bleomycin - adverse effects ; COPPEBVCAD ; Cyclophosphamide - adverse effects ; Dacarbazine - adverse effects ; Doxorubicin - adverse effects ; Etoposide - adverse effects ; Female ; Hematopoietic Stem Cells - drug effects ; Hodgkin Disease - drug therapy ; Hodgkin's lymphoma ; Humans ; Long-term culture-initiating cell ; Male ; Middle Aged ; Myelosuppression ; Prednisone - adverse effects ; Procarbazine - adverse effects ; Vinblastine - adverse effects ; Vincristine - adverse effects</subject><ispartof>Clinical lymphoma & myeloma, 2009-12, Vol.9 (6), p.425-429</ispartof><rights>2009 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c374t-9f36f0e7db94e3b271d47ed7bcb69776abe3384ea697161c8e6eaacc7b03ff83</citedby><cites>FETCH-LOGICAL-c374t-9f36f0e7db94e3b271d47ed7bcb69776abe3384ea697161c8e6eaacc7b03ff83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27915,27916</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19951881$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gobbi, Paolo G.</creatorcontrib><creatorcontrib>Rosti, Vittorio</creatorcontrib><creatorcontrib>Valentino, Francesco</creatorcontrib><creatorcontrib>Bonetti, Elisa</creatorcontrib><creatorcontrib>Merli, Francesco</creatorcontrib><creatorcontrib>Stelitano, Caterina</creatorcontrib><creatorcontrib>Dondi, Alessandra</creatorcontrib><creatorcontrib>Quarta, Giovanni</creatorcontrib><creatorcontrib>Falorio, Simona</creatorcontrib><creatorcontrib>Federico, Massimo</creatorcontrib><title>The Early- and Intermediate-Term Toxicity to Primitive Hematopoietic Progenitor Cells of Three Chemotherapy Regimens for Advanced Hodgkin Lymphoma</title><title>Clinical lymphoma & myeloma</title><addtitle>Clin Lymphoma Myeloma</addtitle><description>The early stem cell reservoir can be impaired by a few cycles of chemotherapy, and this impairment might persist after normalization of peripheral cytopenias. We directly evaluated the damage caused to marrow progenitor cells by 3 currently used chemotherapy regimens for advanced Hodgkin lymphoma.
Bone marrow samples from 37 patients randomly treated according to either the ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine), COPPEBVCAD (cyclophosphamide/vincristine/procarbazine/prednisone/epirubicin/bleomycin/vinblastine/lomustine/melphalan/vindesine), or BEACOPP (bleomycin/etoposide/doxorubicin/cyclophosphamide/vincristine/procarbazine/prednisone)schedule were taken a few days before the start of chemotherapy and 30 days and 6 months after its completion. Samples were cryopreserved, thawed in a single session, and cultured for 5 weeks to detect long-term culture-initiating cells (LTC-IC).
On the basis of the numbers of LTC-IC detected and of their relative variations, the ABVD regimen was associated with the least early reduction and the best late recovery of LTC-IC. COPPEBVCAD produced the greatest early damage, but recovery was nearly complete by 6 months. BEACOPP caused intermediate early toxicity that persisted at 6 months.
The different late toxicity exerted on marrow progenitors by these chemotherapy regimens should be carefully weighed in relation to both the expected early response rate and subsequent possibility of rescue in the case of first treatment failure.</description><subject>ABVD</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>BEACOPP</subject><subject>Bleomycin - adverse effects</subject><subject>COPPEBVCAD</subject><subject>Cyclophosphamide - adverse effects</subject><subject>Dacarbazine - adverse effects</subject><subject>Doxorubicin - adverse effects</subject><subject>Etoposide - adverse effects</subject><subject>Female</subject><subject>Hematopoietic Stem Cells - drug effects</subject><subject>Hodgkin Disease - drug therapy</subject><subject>Hodgkin's lymphoma</subject><subject>Humans</subject><subject>Long-term culture-initiating cell</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Myelosuppression</subject><subject>Prednisone - adverse effects</subject><subject>Procarbazine - adverse effects</subject><subject>Vinblastine - adverse effects</subject><subject>Vincristine - adverse effects</subject><issn>1557-9190</issn><issn>1938-0712</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kcFv2yAYxa1p09q1ve44cdrNHgTHwLGy2qVSplaT7wjD55gtBg9IVP8b-4tHlEg97fS9D_14gveK4jPBFeWk-dZuf1QrjEXlKszrd8U1EZSXmJHV-6zXa1YKIvBV8SnGXxjXa8LIx-KKCLEmnJPr4m83AnpQYb-USDmDnlyCMIGxKkHZZYk6_2q1TQtKHr0EO9lkj4A2MKnkZ28hWZ3P_Q6cTT6gFvb7iPyAujEAoHaEyacRgpoX9BN2dgIX0ZDBe3NUToNBG292v61D22WaRz-p2-LDoPYR7i7zpugeH7p2U26fvz-199tSU1anUgy0GTAw04saaL9ixNQMDOt13wjGGtUDpbwGlTfSEM2hAaW0Zj2mw8DpTfH1bDsH_-cAMcnJRp1frxz4Q5QrQmvMaJPB6gzq4GMMMMg5x6DCIgmWpxJkLkGeSpBO5hLyhS8X50Ofo3zDL6lngJ8ByN87WggyagunMGwAnaTx9n_e_wCxVJjn</recordid><startdate>200912</startdate><enddate>200912</enddate><creator>Gobbi, Paolo G.</creator><creator>Rosti, Vittorio</creator><creator>Valentino, Francesco</creator><creator>Bonetti, Elisa</creator><creator>Merli, Francesco</creator><creator>Stelitano, Caterina</creator><creator>Dondi, Alessandra</creator><creator>Quarta, Giovanni</creator><creator>Falorio, Simona</creator><creator>Federico, Massimo</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope></search><sort><creationdate>200912</creationdate><title>The Early- and Intermediate-Term Toxicity to Primitive Hematopoietic Progenitor Cells of Three Chemotherapy Regimens for Advanced Hodgkin Lymphoma</title><author>Gobbi, Paolo G. ; Rosti, Vittorio ; Valentino, Francesco ; Bonetti, Elisa ; Merli, Francesco ; Stelitano, Caterina ; Dondi, Alessandra ; Quarta, Giovanni ; Falorio, Simona ; Federico, Massimo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c374t-9f36f0e7db94e3b271d47ed7bcb69776abe3384ea697161c8e6eaacc7b03ff83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>ABVD</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>BEACOPP</topic><topic>Bleomycin - adverse effects</topic><topic>COPPEBVCAD</topic><topic>Cyclophosphamide - adverse effects</topic><topic>Dacarbazine - adverse effects</topic><topic>Doxorubicin - adverse effects</topic><topic>Etoposide - adverse effects</topic><topic>Female</topic><topic>Hematopoietic Stem Cells - drug effects</topic><topic>Hodgkin Disease - drug therapy</topic><topic>Hodgkin's lymphoma</topic><topic>Humans</topic><topic>Long-term culture-initiating cell</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Myelosuppression</topic><topic>Prednisone - adverse effects</topic><topic>Procarbazine - adverse effects</topic><topic>Vinblastine - adverse effects</topic><topic>Vincristine - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gobbi, Paolo G.</creatorcontrib><creatorcontrib>Rosti, Vittorio</creatorcontrib><creatorcontrib>Valentino, Francesco</creatorcontrib><creatorcontrib>Bonetti, Elisa</creatorcontrib><creatorcontrib>Merli, Francesco</creatorcontrib><creatorcontrib>Stelitano, Caterina</creatorcontrib><creatorcontrib>Dondi, Alessandra</creatorcontrib><creatorcontrib>Quarta, Giovanni</creatorcontrib><creatorcontrib>Falorio, Simona</creatorcontrib><creatorcontrib>Federico, Massimo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Clinical lymphoma & myeloma</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gobbi, Paolo G.</au><au>Rosti, Vittorio</au><au>Valentino, Francesco</au><au>Bonetti, Elisa</au><au>Merli, Francesco</au><au>Stelitano, Caterina</au><au>Dondi, Alessandra</au><au>Quarta, Giovanni</au><au>Falorio, Simona</au><au>Federico, Massimo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Early- and Intermediate-Term Toxicity to Primitive Hematopoietic Progenitor Cells of Three Chemotherapy Regimens for Advanced Hodgkin Lymphoma</atitle><jtitle>Clinical lymphoma & myeloma</jtitle><addtitle>Clin Lymphoma Myeloma</addtitle><date>2009-12</date><risdate>2009</risdate><volume>9</volume><issue>6</issue><spage>425</spage><epage>429</epage><pages>425-429</pages><issn>1557-9190</issn><eissn>1938-0712</eissn><abstract>The early stem cell reservoir can be impaired by a few cycles of chemotherapy, and this impairment might persist after normalization of peripheral cytopenias. We directly evaluated the damage caused to marrow progenitor cells by 3 currently used chemotherapy regimens for advanced Hodgkin lymphoma.
Bone marrow samples from 37 patients randomly treated according to either the ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine), COPPEBVCAD (cyclophosphamide/vincristine/procarbazine/prednisone/epirubicin/bleomycin/vinblastine/lomustine/melphalan/vindesine), or BEACOPP (bleomycin/etoposide/doxorubicin/cyclophosphamide/vincristine/procarbazine/prednisone)schedule were taken a few days before the start of chemotherapy and 30 days and 6 months after its completion. Samples were cryopreserved, thawed in a single session, and cultured for 5 weeks to detect long-term culture-initiating cells (LTC-IC).
On the basis of the numbers of LTC-IC detected and of their relative variations, the ABVD regimen was associated with the least early reduction and the best late recovery of LTC-IC. COPPEBVCAD produced the greatest early damage, but recovery was nearly complete by 6 months. BEACOPP caused intermediate early toxicity that persisted at 6 months.
The different late toxicity exerted on marrow progenitors by these chemotherapy regimens should be carefully weighed in relation to both the expected early response rate and subsequent possibility of rescue in the case of first treatment failure.</abstract><cop>United States</cop><pmid>19951881</pmid><doi>10.3816/CLM.2009.n.084</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1557-9190 |
| ispartof | Clinical lymphoma & myeloma, 2009-12, Vol.9 (6), p.425-429 |
| issn | 1557-9190 1938-0712 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_21340736 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | ABVD Adolescent Adult Antineoplastic Combined Chemotherapy Protocols - adverse effects BEACOPP Bleomycin - adverse effects COPPEBVCAD Cyclophosphamide - adverse effects Dacarbazine - adverse effects Doxorubicin - adverse effects Etoposide - adverse effects Female Hematopoietic Stem Cells - drug effects Hodgkin Disease - drug therapy Hodgkin's lymphoma Humans Long-term culture-initiating cell Male Middle Aged Myelosuppression Prednisone - adverse effects Procarbazine - adverse effects Vinblastine - adverse effects Vincristine - adverse effects |
| title | The Early- and Intermediate-Term Toxicity to Primitive Hematopoietic Progenitor Cells of Three Chemotherapy Regimens for Advanced Hodgkin Lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T01%3A10%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Early-%20and%20Intermediate-Term%20Toxicity%20to%20Primitive%20Hematopoietic%20Progenitor%20Cells%20of%20Three%20Chemotherapy%20Regimens%20for%20Advanced%20Hodgkin%20Lymphoma&rft.jtitle=Clinical%20lymphoma%20&%20myeloma&rft.au=Gobbi,%20Paolo%20G.&rft.date=2009-12&rft.volume=9&rft.issue=6&rft.spage=425&rft.epage=429&rft.pages=425-429&rft.issn=1557-9190&rft.eissn=1938-0712&rft_id=info:doi/10.3816/CLM.2009.n.084&rft_dat=%3Cproquest_cross%3E21340736%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=21340736&rft_id=info:pmid/19951881&rft_els_id=S1557919011700336&rfr_iscdi=true |